CeriBell, Inc., a commercial-stage medical technology company focused on diagnosis and management of serious neurological conditions, has priced its initial public offering of 10.61 million shares at $17 each.
The company's flagship product, Ceribell System, is an EEG (ElectroEncephaloGraphy) device that combines AI-powered algorithms with easy-to-use hardware, to monitor patient seizures in the acute care setting.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com